Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Open Closes January 7, 2028 (433 days left) Opportunity PAR-25-145

National Institutes of Health is offering grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications close on January 7, 2028.

From the official notice on Grants.gov, last changed November 6, 2024. Checked October 31, 2026.

Key dates

PostedNovember 6, 2024
DeadlineJanuary 7, 2028
Archived by Grants.govFebruary 12, 2028

Add the deadline to your calendar

Who can apply

This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Category: Education, Health.

How to apply

  1. Read the full notice and attachments on Grants.gov and the agency's announcement. The notice is the official source for deadlines and requirements.
  2. Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
  3. Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.

Questions go to National Institutes of Health, grantsinfo@nih.gov, 301-402-2541.

Open the official notice

Questions people ask

Who can apply for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)?

Closes January 7, 2028 (433 days left). Confirm the date and time in the official notice on Grants.gov.

Similar open grants